OSA's Digital Library

Biomedical Optics Express

Biomedical Optics Express

  • Editor: Joseph A. Izatt
  • Vol. 5, Iss. 1 — Jan. 1, 2014
  • pp: 183–196

Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents

Funda Meric-Bernstam, John C. Rasmussen, Savitri Krishnamurthy, I-Chih Tan, Banghe Zhu, Jamie L. Wagner, Gildy V. Babiera, Elizabeth A. Mittendorf, and Eva M. Sevick-Muraca  »View Author Affiliations


Biomedical Optics Express, Vol. 5, Issue 1, pp. 183-196 (2014)
http://dx.doi.org/10.1364/BOE.5.000183


View Full Text Article

Enhanced HTML    Acrobat PDF (5288 KB)





Browse Journals / Lookup Meetings

Browse by Journal and Year


   


Lookup Conference Papers

Close Browse Journals / Lookup Meetings

Article Tools

Share
Citations

Abstract

As part of a proof-of-concept study for future delivery of targeted near-infrared fluorescent (NIRF) tracers, we sought to assess the delivery of micrograms of indocyanine green to all the axillary lymph nodes following intraparenchymal breast injections and intradermal arm injections in 20 subjects with advanced breast carcinoma and undergoing complete axillary lymph node dissection. Lymphatic vessels and nodes were assessed in vivo. Ex vivo images demonstrated that 87% of excised lymph nodes, including 81% of tumor-positive lymph nodes, were fluorescent. Future clinical studies using microdose amounts of tumor-targeting NIRF contrast agents may demonstrate improved surgical intervention with reduced morbidity.

© 2013 Optical Society of America

OCIS Codes
(100.2960) Image processing : Image analysis
(170.0110) Medical optics and biotechnology : Imaging systems
(170.1610) Medical optics and biotechnology : Clinical applications
(170.3880) Medical optics and biotechnology : Medical and biological imaging

ToC Category:
Optics in Cancer Research

History
Original Manuscript: August 30, 2013
Revised Manuscript: November 28, 2013
Manuscript Accepted: December 4, 2013
Published: December 13, 2013

Citation
Funda Meric-Bernstam, John C. Rasmussen, Savitri Krishnamurthy, I-Chih Tan, Banghe Zhu, Jamie L. Wagner, Gildy V. Babiera, Elizabeth A. Mittendorf, and Eva M. Sevick-Muraca, "Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents," Biomed. Opt. Express 5, 183-196 (2014)
http://www.opticsinfobase.org/boe/abstract.cfm?URI=boe-5-1-183


Sort:  Author  |  Year  |  Journal  |  Reset  

References

  1. S. A. McLaughlin, M. J. Wright, K. T. Morris, G. L. Giron, M. R. Sampson, J. P. Brockway, K. E. Hurley, E. R. Riedel, and K. J. Van Zee, “Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: Objective measurements,” J. Clin. Oncol.26(32), 5213–5219 (2008). [CrossRef] [PubMed]
  2. S. A. Norman, A. R. Localio, S. L. Potashnik, H. A. Simoes Torpey, M. J. Kallan, A. L. Weber, L. T. Miller, A. Demichele, and L. J. Solin, “Lymphedema in breast cancer survivors: Incidence, degree, time course, treatment, and symptoms,” J. Clin. Oncol.27(3), 390–397 (2008). [CrossRef] [PubMed]
  3. J. A. Petrek, R. T. Senie, M. Peters, and P. P. Rosen, “Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis,” Cancer92(6), 1368–1377 (2001). [CrossRef] [PubMed]
  4. C. Boneti, S. Korourian, Z. Diaz, C. Santiago, S. Mumford, L. Adkins, and V. S. Klimberg, “Scientific impact award: Axillary reverse mapping (arm) to identify and protect lymphatics draining the arm during axillary lymphadenectomy,” Am. J. Surg.198(4), 482–487 (2009). [CrossRef] [PubMed]
  5. M. Thompson, S. Korourian, R. Henry-Tillman, L. Adkins, S. Mumford, K. C. Westbrook, and V. S. Klimberg, “Axillary reverse mapping (arm): A new concept to identify and enhance lymphatic preservation,” Ann. Surg. Oncol.14(6), 1890–1895 (2007). [CrossRef] [PubMed]
  6. J. W. Han, Y. J. Seo, J. E. Choi, S. H. Kang, Y. K. Bae, and S. J. Lee, “The efficacy of arm node preserving surgery using axillary reverse mapping for preventing lymphedema in patients with breast cancer,” J. Breast Cancer15(1), 91–97 (2012). [CrossRef] [PubMed]
  7. T. B. Britton, C. K. Solanki, S. E. Pinder, P. S. Mortimer, A. M. Peters, and A. D. Purushotham, “Lymphatic drainage pathways of the breast and the upper limb,” Nucl. Med. Commun.30(6), 427–430 (2009). [CrossRef] [PubMed]
  8. J. E. Choi, Y. S. Jeon, S. H. Kang, and S. J. Lee, “Preservation of lymphatic drainage of arm during axillary procedure in breast cancer patients,” J. Breast Cancer12(3), 179–185 (2009). [CrossRef]
  9. R. Ponzone, N. T. Cont, F. Maggiorotto, E. Cassina, P. Mininanni, N. Biglia, and P. Sismondi, “Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer,” J. Clin. Oncol.27(33), 5547–5551 (2009). [CrossRef] [PubMed]
  10. I. Bedrosian, G. V. Babiera, E. A. Mittendorf, H. M. Kuerer, L. Pantoja, K. K. Hunt, S. Krishnamurthy, and F. Meric-Bernstam, “A phase i study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients,” Cancer116(11), 2543–2548 (2010). [PubMed]
  11. M. A. Hall, S. Kwon, H. Robinson, P.-A. Lachance, A. Azhdarinia, R. Ranganathan, R. E. Price, W. Chan, and E. M. Sevick-Muraca, “Imaging prostate cancer lymph node metastases with a multimodality contrast agent,” Prostate72(2), 129–146 (2012). [CrossRef] [PubMed]
  12. M. A. Hall, K. L. Pinkston, N. Wilganowski, H. Robinson, P. Ghosh, A. Azhdarinia, K. Vazquez-Arreguin, A. M. Kolonin, B. R. Harvey, and E. M. Sevick-Muraca, “Comparison of mabs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: Quantitative small-animal pet/ct and nirf,” J. Nucl. Med.53(9), 1427–1437 (2012). [CrossRef] [PubMed]
  13. N. K. Tafreshi, M. M. Bui, K. Bishop, M. C. Lloyd, S. A. Enkemann, A. S. Lopez, D. Abrahams, B. W. Carter, J. Vagner, S. R. Grobmyer, R. J. Gillies, and D. L. Morse, “Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases ix and xii targeted imaging probes,” Clin. Cancer Res.18(1), 207–219 (2012). [CrossRef] [PubMed]
  14. C. H. Heath, N. L. Deep, L. N. Beck, K. E. Day, L. Sweeny, K. R. Zinn, C. C. Huang, and E. L. Rosenthal, “Use of panitumumab-irdye800 to image cutaneous head and neck cancer in mice,” Otolaryngol. Head Neck Surg.148(6), 982–990 (2013). [CrossRef] [PubMed]
  15. F. Wu, M. Tamhane, and M. E. Morris, “Pharmacokinetics, lymph node uptake, and mechanistic pk model of near-infrared dye-labeled bevacizumab after iv and sc administration in mice,” AAPS J.14(2), 252–261 (2012). [CrossRef] [PubMed]
  16. J. Wu, R. Ma, H. Cao, Z. Wang, C. Jing, Y. Sun, Y. Zhang, Z. Yang, R. M. Hoffman, and J. Tang, “Intraoperative imaging of metastatic lymph nodes using a fluorophore-conjugated antibody in a her2/neu-expressing orthotopic breast cancer mouse model,” Anticancer Res.33(2), 419–424 (2013). [PubMed]
  17. L. Sampath, W. Wang, and E. M. Sevick-Muraca, “Near infrared fluorescent optical imaging for nodal staging,” J. Biomed. Opt.13(4), 041312 (2008). [CrossRef] [PubMed]
  18. T. Kitai, T. Inomoto, M. Miwa, and T. Shikayama, “Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer,” Breast Cancer12(3), 211–215 (2005). [CrossRef] [PubMed]
  19. E. M. Sevick-Muraca, R. Sharma, J. C. Rasmussen, M. V. Marshall, J. A. Wendt, H. Q. Pham, E. Bonefas, J. P. Houston, L. Sampath, K. E. Adams, D. K. Blanchard, R. E. Fisher, S. B. Chiang, R. Elledge, and M. E. Mawad, “Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: Feasibility study,” Radiology246(3), 734–741 (2008). [CrossRef] [PubMed]
  20. D. Murawa, C. Hirche, S. Dresel, and M. Hünerbein, “Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence,” Br. J. Surg.96(11), 1289–1294 (2009). [CrossRef] [PubMed]
  21. A. Hirano, M. Kamimura, K. Ogura, N. Kim, A. Hattori, Y. Setoguchi, F. Okubo, H. Inoue, R. Miyamoto, J. Kinoshita, M. Fujibayashi, and T. Shimizu, “A comparison of indocyanine green fluorescence imaging plus blue dye and blue dye alone for sentinel node navigation surgery in breast cancer patients,” Ann. Surg. Oncol.19(13), 4112–4116 (2012). [CrossRef] [PubMed]
  22. J. R. van der Vorst, B. E. Schaafsma, F. P. Verbeek, M. Hutteman, J. S. Mieog, C. W. Lowik, G. J. Liefers, J. V. Frangioni, C. J. van de Velde, and A. L. Vahrmeijer, “Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients,” Ann. Surg. Oncol.19(13), 4104–4111 (2012). [CrossRef] [PubMed]
  23. B. E. Schaafsma, F. P. Verbeek, D. D. Rietbergen, B. van der Hiel, J. R. van der Vorst, G. J. Liefers, J. V. Frangioni, C. J. van de Velde, F. W. van Leeuwen, and A. L. Vahrmeijer, “Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer,” Br. J. Surg.100(8), 1037–1044 (2013). [CrossRef] [PubMed]
  24. M. Takeuchi, T. Sugie, K. Abdelazeem, H. Kato, N. Shinkura, M. Takada, H. Yamashiro, T. Ueno, and M. Toi, “Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer,” Breast J.18(6), 535–541 (2012). [CrossRef] [PubMed]
  25. G. C. Wishart, S. W. Loh, L. Jones, and J. R. Benson, “A feasibility study (icg-10) of indocyanine green (icg) fluorescence mapping for sentinel lymph node detection in early breast cancer,” Eur. J. Surg. Oncol.38(8), 651–656 (2012). [CrossRef] [PubMed]
  26. T. Sugie, T. Sawada, N. Tagaya, T. Kinoshita, K. Yamagami, H. Suwa, T. Ikeda, K. Yoshimura, M. Niimi, A. Shimizu, and M. Toi, “Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer,” Ann. Surg. Oncol.20(7), 2213–2218 (2013). [CrossRef] [PubMed]
  27. J. C. Rasmussen, S. Kwon, E. M. Sevick-Muraca, and J. N. Cormier, “The role of lymphatics in cancer as assessed by near-infrared fluorescence imaging,” Ann. Biomed. Eng.40(2), 408–421 (2012). [CrossRef] [PubMed]
  28. M. L. Landsman, G. Kwant, G. A. Mook, and W. G. Zijlstra, “Light-absorbing properties, stability, and spectral stabilization of indocyanine green,” J. Appl. Physiol.40(4), 575–583 (1976). [PubMed]
  29. E. M. Sevick-Muraca and J. C. Rasmussen, “Molecular imaging with optics: Primer and case for near-infrared fluorescence techniques in personalized medicine,” J. Biomed. Opt.13(4), 041303 (2008). [CrossRef] [PubMed]
  30. B. Zhu, J. C. Rasmussen, and E. M. Sevick-Muraca, “A matter of collection and detection for intraoperative and non-invasive fluorescence molecular imaging: To see or not to see?,” Medical Physics accepted with revision (2013).
  31. B. Zhu, I.-C. Tan, J. C. Rasmussen, and E. M. Sevick-Muraca, “Validating the sensitivity and performance of near-infrared fluorescence imaging and tomography devices using a novel solid phantom and measurement approach,” Technol. Cancer Res. Treat.11(1), 95–104 (2012). [PubMed]
  32. J. C. Rasmussen, I. C. Tan, M. V. Marshall, K. E. Adams, S. Kwon, C. E. Fife, E. A. Maus, L. A. Smith, K. R. Covington, and E. M. Sevick-Muraca, “Human lymphatic architecture and dynamic transport imaged using near-infrared fluorescence,” Transl. Oncol.3(6), 362–372 (2010). [PubMed]
  33. J. C. Rasmussen, I. C. Tan, M. V. Marshall, C. E. Fife, and E. M. Sevick-Muraca, “Lymphatic imaging in humans with near-infrared fluorescence,” Curr. Opin. Biotechnol.20(1), 74–82 (2009). [CrossRef] [PubMed]
  34. P. E. Burrows, M. L. Gonzalez-Garay, J. C. Rasmussen, M. B. Aldrich, R. Guilliod, E. A. Maus, C. E. Fife, S. Kwon, P. E. Lapinski, P. D. King, and E. M. Sevick-Muraca, “Lymphatic abnormalities are associated with rasa1 gene mutations in mouse and man,” Proc. Natl. Acad. Sci. U.S.A.110(21), 8621–8626 (2013). [CrossRef] [PubMed]
  35. E. M. Sevick-Muraca and B. Zhu, “The need for performance standards in clinical translation and adoption of fluorescence molecular imaging,” Med. Phys.40(4), 040402 (2013). [CrossRef] [PubMed]
  36. S. Hirakawa, L. F. Brown, S. Kodama, K. Paavonen, K. Alitalo, and M. Detmar, “Vegf-c-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites,” Blood109(3), 1010–1017 (2006). [CrossRef] [PubMed]
  37. M. I. Harrell, B. M. Iritani, and A. Ruddell, “Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis,” Am. J. Pathol.170(2), 774–786 (2007). [CrossRef] [PubMed]
  38. K. Alitalo, T. Tammela, and T. V. Petrova, “Lymphangiogenesis in development and human disease,” Nature438(7070), 946–953 (2005). [CrossRef] [PubMed]
  39. R. C. Ji, “Lymph node lymphangiogenesis: A new concept for modulating tumor metastasis and inflammatory process,” Histol. Histopathol.24(3), 377–384 (2009). [PubMed]
  40. T. Karpanen and K. Alitalo, “Molecular biology and pathology of lymphangiogenesis,” Annu. Rev. Pathol.3(1), 367–397 (2008). [CrossRef] [PubMed]
  41. J. A. P. Leijte, I. M. C. van der Ploeg, R. A. Valdés Olmos, O. E. Nieweg, and S. Horenblas, “Visualization of tumor blockage and rerouting of lymphatic drainage in penile cancer patients by use of spect/ct,” J. Nucl. Med.50(3), 364–367 (2009). [CrossRef] [PubMed]
  42. “Guidance for industry, investigators, and reviewers: Exploratory IND studies,” U.S. Department of Health and Human Services, and C. D. E. R. Food and Drug Administration, eds. (2006).

Cited By

Alert me when this paper is cited

OSA is able to provide readers links to articles that cite this paper by participating in CrossRef's Cited-By Linking service. CrossRef includes content from more than 3000 publishers and societies. In addition to listing OSA journal articles that cite this paper, citing articles from other participating publishers will also be listed.

Supplementary Material


» Media 1: AVI (1710 KB)     

« Previous Article  |  Next Article »

OSA is a member of CrossRef.

CrossCheck Deposited